Skip to main content

Agios ex-CEO joins GV as life sciences investment team's co-head

After handing over control of one of the Bay State's most promising commercial biotech companies, David Schenkein is joining GV as a the co-head of its life sciences investment branch.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.